ライフサイエンスコーパス: ventilator-associated pneumonia

1 outcome that was not targeted by the policy (ventilator-associated pneumonia).

2 ilator-associated complication, and probable ventilator-associated pneumonia.

3 Primary endpoint was the rate of ventilator-associated pneumonia.

4 t demonstrate older age as a risk factor for ventilator-associated pneumonia.

5 ubglottic secretions plays a pivotal role in ventilator-associated pneumonia.

6 s has been implicated in the pathogenesis of ventilator-associated pneumonia.

7 l care strategies involving toothbrushing on ventilator-associated pneumonia.

8 with or without toothbrushing, and examined ventilator-associated pneumonia.

9 r some types of infection, in particular for ventilator-associated pneumonia.

10 the lowest concordance observed in cases of ventilator-associated pneumonia.

11 tive incidence of bloodstream infections and ventilator-associated pneumonia.

12 l care to evaluate its potential to decrease ventilator-associated pneumonia.

13 ve surveillance methods for the diagnosis of ventilator-associated pneumonia.

14 . aureus coverage in patients with suspected ventilator-associated pneumonia.

15 l criteria for establishing the diagnosis of ventilator-associated pneumonia.

16 ssfully implement programs aimed at reducing ventilator-associated pneumonia.

17 ssociated with a propensity to posttraumatic ventilator-associated pneumonia.

18 ating objective surveillance definitions for ventilator-associated pneumonia.

19 velopment of methicillin-resistant S. aureus ventilator-associated pneumonia.

20 rveillance culture before the development of ventilator-associated pneumonia.

21 age as a way to predict their involvement in ventilator-associated pneumonia.

22 ccus aureus has emerged as a common cause of ventilator-associated pneumonia.

23 ared with the patients who had P. aeruginosa ventilator-associated pneumonia.

24 egrees -45 degrees to prevent aspiration and ventilator-associated pneumonia.

25 e at particular risk for pressure ulcers and ventilator-associated pneumonia.

26 al care can mimic the clinical appearance of ventilator-associated pneumonia.

27 pneumonia and during critical illness causes ventilator-associated pneumonia.

28 rial dilution techniques in the diagnosis of ventilator-associated pneumonia.

29 avage samples of 104 patients with suspected ventilator-associated pneumonia.

30 icians in limiting, identifying and treating ventilator-associated pneumonia.

31 mes for patients suspected of suffering from ventilator-associated pneumonia.

32 c bronchoalveolar lavage in the diagnosis of ventilator-associated pneumonia.

33 ith subglottic secretion drainage to prevent ventilator-associated pneumonia.

34 (CASS) is believed to lower the incidence of ventilator-associated pneumonia.

35 tudies describing the costs and outcomes for ventilator-associated pneumonia.

36 ternative to vancomycin for the treatment of ventilator-associated pneumonia.

37 rticular for catheter-related infections and ventilator-associated pneumonia.

38 inezolid was cost-effective for treatment of ventilator-associated pneumonia.

39 followed prospectively for the occurrence of ventilator-associated pneumonia.

40 difficult-to-treat pathogens likely to cause ventilator-associated pneumonia.

41 n the intensive care unit was complicated by ventilator-associated pneumonia.

42 in the intensive-care unit and incidence of ventilator-associated pneumonia.

43 more related to other medical features than ventilator-associated pneumonia.

44 ould be a promising therapeutic strategy for ventilator-associated pneumonia.

45 obials or as monotherapy in the treatment of ventilator-associated pneumonia.

46 imary role of gravity in the pathogenesis of ventilator-associated pneumonia.

47 in the intensive-care unit and incidence of ventilator-associated pneumonia.

48 ssociated condition constructs for detecting ventilator-associated pneumonia.

49 oportion of standardized cases classified as ventilator-associated pneumonia.

50 f oropharyngeal pathogens and development of ventilator-associated pneumonia.

51 ients with respiratory tract colonization or ventilator- associated pneumonia.

52 ve infections, such as hospital-acquired and ventilator-associated pneumonias.

53 catheter-related bloodstream infections and ventilator-associated pneumonias.

54 The prevalence (n ventilator-associated pneumonia/1,000 ventilation days)

55 mial infections (27.3% and 43.8%), including ventilator-associated pneumonia (14.5% and 27.6%).

56 Rates of ventilator-associated pneumonia (20% vs. 21%, p=.94), vo

57 Among the 47 patients with ventilator-associated pneumonia, 25 (58.2%) experienced

58 ction were bloodstream infection (64.3%) and ventilator-associated pneumonia (35.7%).

59 Among 587 patients with suspected ventilator-associated pneumonia, 40 (6.8%) were colonize

60 . 3.1 +/- 2.7 days, p < 0.001), and rates of ventilator-associated pneumonia (42.5% vs. 8.0%; p < 0.0

61 OR, 30.7 [95% CI, 19.3-49.2]), prevention of ventilator-associated pneumonia (52% vs 33%, respectivel

62 ted urinary tract infection, 13 versus 8 for ventilator-associated pneumonia, 6 versus 3 for incision

63 (29% baseline vs. 26% cycling; p = .11) and ventilator-associated pneumonia (80% vs. 41%; p = .06) d

64 iratory specimen Gram stain for diagnosis of ventilator-associated pneumonia, absence of bacteria on

65 Of these, 83 patients (4%) had ventilator-associated pneumonia according to the America

66 >/=6 and >/=14 days had greater reduction in ventilator-associated pneumonia acquisition and also had

67 Invasive approaches to ventilator-associated pneumonia affect antibiotic use an

68 role of improved diagnosis and prevention of ventilator-associated pneumonia also showed relevant res

69 ed with improved outcome in the treatment of ventilator-associated pneumonia although the level of ev

70 Two hundred eight patients had ventilator-associated pneumonia and 135 had nonventilato

71 7 (9.5%) had methicillin-resistant S. aureus ventilator-associated pneumonia and 54 (13.9%) had methi

72 d administration of systemic antibiotics for ventilator-associated pneumonia and any other infection.

73 Ventilator-associated pneumonia and bleed are the variab

74 nd survival were the assumptions surrounding ventilator-associated pneumonia and bleed.

75 ing; the effect of proton pump inhibitors on ventilator-associated pneumonia and C. difficile remain

76 t Staphylococcus aureus is a common cause of ventilator-associated pneumonia and can be identified by

77 Mean rates of ventilator-associated pneumonia and catheter-related blo

78 Ventilator-associated pneumonia and catheter-related blo

79 unit and hospital length of stay, rates for ventilator-associated pneumonia and central venous acces

80 length of stay and lowered the prevalence of ventilator-associated pneumonia and central venous acces

81 ved from prospective trials of linezolid for ventilator-associated pneumonia and from other studies d

82 patients did not meet clinical criteria for ventilator-associated pneumonia and had a statistically

83 aureus as an etiology in most patients with ventilator-associated pneumonia and may decrease the nee

84 to reduce infectious complications including ventilator-associated pneumonia and may influence intens

85 ely ill population with clinically suspected ventilator-associated pneumonia and negative quantitativ

86 considered, as well as when stratified into ventilator-associated pneumonia and nonventilator ICU-ac

87 accurately predicted patients that developed ventilator-associated pneumonia and should now be tested

88 Use of aerosolised antibiotics for ventilator-associated pneumonia and ventilator-associate

89 Effective (aerosolized antibiotics for ventilator-associated pneumonia) and ineffective (procal

90 ship between ventilator-associated event and ventilator-associated pneumonia, and 3) the impact of ve

91 ly significant stress-related mucosal bleed, ventilator-associated pneumonia, and Clostridium diffici

92 fied acute physiology score II, diagnosis of ventilator-associated pneumonia, and infection by multid

93 nit (ICU) most commonly manifests as sepsis, ventilator-associated pneumonia, and infection of surgic

94 catheter-associated bloodstream infections, ventilator-associated pneumonia, and other healthcare-as

95 ement initiatives aimed at the prevention of ventilator-associated pneumonia, and other ventilator-as

96 redictor for methicillin-resistant S. aureus ventilator-associated pneumonia are 70.3% (95% confidenc

97 Issues related to ventilator-associated pneumonia are now particularly acu

98 Septicemia and ventilator-associated pneumonia are two of the more seve

99 ke surveillance of events possibly linked to ventilator-associated pneumonia as objective as possible

100 standardized vignettes of possible cases of ventilator-associated pneumonia as pneumonia or no pneum

101 e of the bacterial pathogens associated with ventilator-associated pneumonia, as well as with other n

102 rend shows a 55.83% reduction in the rate of ventilator-associated pneumonia at the end of the study

103 oalveolar lavage to allow rapid diagnosis of ventilator associated pneumonia attributable to methicil

104 When excluding the ten patients who had ventilator-associated pneumonia attributed to bacteria o

105 ion and critical illness were identified: a) ventilator-associated pneumonia; b) upper gastrointestin

106 ventilator-associated pneumonia did not have ventilator-associated pneumonia because radiographic cri

107 ntibiotics for more than 5 days for treating ventilator-associated pneumonia before the occurrence of

108 alter antibiotic management in patients with ventilator-associated pneumonia but would not necessaril

109 conducted active prospective surveillance of ventilator-associated pneumonia by applying the definiti

110 significantly associated with P. aeruginosa ventilator-associated pneumonia by multivariate logistic

111 ion constructs detected less than a third of ventilator-associated pneumonia cases with a sensitivity

112 ver the study period, 20 patients (3.4%) had ventilator-associated pneumonia caused by extended-spect

113 atients with nosocomial pneumonia (including ventilator-associated pneumonia) caused by Gram-negative

114 The pooled incidence density of ventilator-associated pneumonia, central line-associated

115 icularly damaging or fatal for patients with ventilator-associated pneumonia, chronic obstructive pul

116 atients with nosocomial pneumonia, including ventilator-associated pneumonia, compared with meropenem

117 enced-based interventions reduce the risk of ventilator-associated pneumonia, controversy has surroun

118 s who had high P. aeruginosa burdens and met ventilator-associated pneumonia criteria.

119 During the study period, ventilator-associated pneumonia decreased from 2.50 to 1

120 all p<0.03); and had no change in mortality, ventilator-associated pneumonia, deep vein thrombosis, d

121 ructs failed to detect many patients who had ventilator-associated pneumonia, detected many cases tha

122 Ventilator-associated pneumonia developed in 20.4% of pa

123 Ventilator-associated pneumonia developed in 66.67%, 85.

124 secretion drainage is associated with fewer ventilator-associated pneumonia diagnoses, but it is unc

125 Ventilator-associated pneumonia diagnosis remains a deba

126 with National Health Safety Network probable ventilator-associated pneumonia did not have ventilator-

127 In this multicenter cohort study, ventilator-associated pneumonia did not occur more frequ

128 inical outcomes (ICU and hospital mortality, ventilator-associated pneumonia, duration of mechanical

129 Infections (especially ventilator-associated pneumonia) during extracorporeal m

130 nd in vivo efficacy against strain 536 and a ventilator-associated pneumonia E. coli were tested.

131 We identified 32 ventilator-associated pneumonia, eight urinary tract inf

132 Adults with nosocomial pneumonia (including ventilator-associated pneumonia), enrolled at 136 centre

133 ntral line-associated bloodstream infection, ventilator-associated pneumonia/events, postprocedure pn

134 The frequency of ventilator-associated pneumonia fell from 8.1% to 1.3% (

135 prospectively and independently screened for ventilator-associated pneumonia from January 2009 to Jan

136 Secondary outcomes included incidence of ventilator-associated pneumonia, gastrointestinal hemorr

137 easure was aggregate concordance with the 14 ventilator-associated pneumonia guideline recommendation

138 A 2-yr multifaceted intervention to enhance ventilator-associated pneumonia guideline uptake was ass

139 s, as strategies to implement evidence-based ventilator-associated pneumonia guidelines on guideline

140 infected, ventilated patients, patients with ventilator-associated pneumonia had a higher Acute Physi

141 inosa who did not meet clinical criteria for ventilator-associated pneumonia had an increased risk of

142 zed invasive techniques for the diagnosis of ventilator-associated pneumonia had lower rates of prolo

143 Patients with ventilator-associated pneumonia had significantly higher

144 Patients with ventilator-associated pneumonia had significantly longer

145 inhibitor use with Clostridium difficile and ventilator-associated pneumonia have raised concerns rec

146 imbursement for patients with development of ventilator-associated pneumonia, hospitals need to devel

147 Accurate diagnosis of ventilator-associated pneumonia, however, is notoriously

148 < 10), including pneumothorax, atelectasis, ventilator-associated pneumonia, hypoglycemia, hyperglyc

149 tive cohort study of patients with suspected ventilator-associated pneumonia in a medical ICU was con

150 Network in 2013, replacing surveillance for ventilator-associated pneumonia in adult inpatient locat

151 We investigated the epidemiology of ventilator-associated pneumonia in elderly ICU patients.

152 Ventilator-associated pneumonia in elderly patients was

153 nd oral care with povidone-iodine to prevent ventilator-associated pneumonia in high-risk patients.

154 cinetobacter baumannii is a leading cause of ventilator-associated pneumonia in intensive care units,

155 volvement of such pathogens in patients with ventilator-associated pneumonia in low-prevalence area.

156 in the intensive care unit in general and of ventilator-associated pneumonia in particular, and offer

157 atients with A. baumannii complex infection, ventilator-associated pneumonia in particular, the selec

158 ultidimensional approach on the reduction of ventilator-associated pneumonia in patients hospitalized

159 Oral care may decrease ventilator-associated pneumonia in the ICU.

160 luminate the full magnitude of the impact of ventilator-associated pneumonia in the intensive care un

161 period, there was a significant reduction in ventilator-associated pneumonia in the postintervention

162 thm for antibiotic discontinuation rules out ventilator-associated pneumonia in the setting of negati

163 Cultures were positive in 88% of ventilator-associated pneumonias in the American College

164 We measured occurrence of ventilator-associated pneumonia, in-hospital mortality r

165 ons (incidence-rate ratio, 1.03; P=0.08), or ventilator-associated pneumonia (incidence-rate ratio, 0

166 catheter-associated urinary tract infection, ventilator-associated pneumonia, incisional surgical sit

167 Ventilator-associated pneumonia is a difficult diagnosis

168 Ventilator-associated pneumonia is an important cause of

169 Ventilator-associated pneumonia is associated with incre

170 has recently proposed a major change in how ventilator-associated pneumonia is defined.

171 esentative study of hospitals, assignment of ventilator-associated pneumonia is extremely variable, e

172 Ventilator-associated pneumonia is frequent in ICUs.

173 Ventilator-associated pneumonia is one of the most commo

174 Ventilator-associated pneumonia is the most common inten

175 Ventilator-associated pneumonia is the most important in

176 to be the gold standard for the diagnosis of ventilator-associated pneumonia, it is more labor intens

177 the prevention, diagnosis, and treatment of ventilator-associated pneumonia may improve outcomes, bu

178 onal Nosocomial Infection Control Consortium ventilator-associated pneumonia multidimensional approac

179 ured trauma patients that went on to develop ventilator-associated pneumonia (n=10) was compared to t

180 g hospitals about classification of cases as ventilator-associated pneumonia/not ventilator-associate

181 Ventilator-associated pneumonia occurred in 103 middle-a

182 Ventilator-associated pneumonia occurred in 127 of 819 p

183 ing ventilation, microbiologically confirmed ventilator-associated pneumonia occurred in 15 patients

184 Ventilator-associated pneumonia occurred in 24 patients

185 ilator-associated complication episodes, and ventilator-associated pneumonia occurrence: R = 0.69 and

186 Ventilator-associated pneumonia occurs in a considerable

187 nd ability to prevent Pseudomonas aeruginosa ventilator-associated pneumonia of KB001, a recombinant,

188 Regarding clinical signs and symptoms at ventilator-associated pneumonia onset, new temperature r

189 easures are poorly correlated with decreased ventilator-associated pneumonia or catheter-related bloo

190 ssociated condition cases (93%) did not have ventilator-associated pneumonia or other hospital-acquir

191 and in high-risk complex infections such as ventilator-associated pneumonia or sepsis where coloniza

192 omplications (1.6% vs 13%, respectively, for ventilator-associated pneumonia [OR, 0.15; 95% CI, 0.09-

193 ing did not significantly reduce the risk of ventilator-associated pneumonia overall.

194 to attenuate the effect of toothbrushing on ventilator-associated pneumonia (p for the interaction =

195 ity in empirically treated, culture-negative ventilator-associated pneumonia patients whose antibioti

196 served in one trial reporting fewer cases of ventilator-associated pneumonia per 1,000 ventilator day

197 d complexity of surveillance definitions for ventilator-associated pneumonia preclude meaningful inte

198 effect of subglottic secretion suctioning on ventilator-associated pneumonia prevalence and to assess

199 Ventilator-associated pneumonia prevalence as defined by

200 oning resulted in a significant reduction of ventilator-associated pneumonia prevalence associated wi

201 Corresponding P. aeruginosa ventilator-associated pneumonia prevalences were 4.1%, 3

202 Implementation of a ventilator-associated pneumonia prevention bundle was as

203 A four-element ventilator-associated pneumonia prevention bundle, consi

204 Existing ventilator-associated pneumonia prevention bundles are u

205 ch had not been achieved with earlier ad hoc ventilator-associated pneumonia prevention guidelines in

206 sociated with a significant reduction in the ventilator-associated pneumonia rate in the adult intens

207 Ventilator-associated pneumonia rate per 100 ventilator

208 at the end of the study period; that is, the ventilator-associated pneumonia rate was 55.83% lower th

209 secretion drainage was associated with lower ventilator-associated pneumonia rates (risk ratio, 0.58;

210 four trials, there was a trend toward lower ventilator-associated pneumonia rates (risk ratio, 0.77;

211 manual toothbrushing showed no difference in ventilator-associated pneumonia rates (risk ratio, 0.96;

212 re considering requiring hospitals to report ventilator-associated pneumonia rates as a way to benchm

213 secretion drainage is associated with lower ventilator-associated pneumonia rates but does not clear

214 Over the study period, ventilator-associated pneumonia rates decreased (events/

215 iated complication and possible and probable ventilator-associated pneumonia rates decreased from 3.1

216 These sources of variability make ventilator-associated pneumonia rates difficult to acqui

217 The ventilator-associated pneumonia rates obtained in phase

218 In terms of ventilatory days, ventilator-associated pneumonia rates were 9.6 of 1,000

219 ventilator-associated pneumonia were pooled, ventilator-associated pneumonia rates were also signific

220 onia guidelines on guideline concordance and ventilator-associated pneumonia rates.

221 in guideline concordance and a reduction in ventilator-associated pneumonia rates.

222 nce; 4) process surveillance; 5) feedback of ventilator-associated pneumonia rates; and 6) performanc

223 Our findings suggest that ventilator-associated pneumonia remains a common ICU inf

224 Ventilator-associated pneumonia remains a major challeng

225 Ventilator-associated pneumonia remains an important top

226 The optimal strategy for ventilator-associated pneumonia remains controversial.

227 head of bed elevation to reduce the risk of ventilator-associated pneumonia, remains unclear.

228 ted that toothbrushing significantly reduced ventilator-associated pneumonia (risk ratio, 0.26; 95% c

229 The use of evidence-based bundles targeting ventilator-associated pneumonia seems to be a reasonable

230 fic interventions to reduce the incidence of ventilator-associated pneumonia: semi-recumbent position

231 Ventilator-associated pneumonia should be excluded from

232 e second group of mice was infected with the ventilator-associated pneumonia strain and received 536_

233 adaptation of this bacteriophage toward the ventilator-associated pneumonia strain led to isolate a

234 The majority of mice infected by the ventilator-associated pneumonia strain were not rescued

235 tion surveillance did not perform as well as ventilator-associated pneumonia surveillance and had sev

236 Individuals responsible for ventilator-associated pneumonia surveillance at 43 U.S.

237 ng limitations of the national definition of ventilator-associated pneumonia that was in place until

238 0 cfu/ml as a criterion for the diagnosis of ventilator-associated pneumonia, there was discordance o

239 ct costs, estimated the attributable cost of ventilator-associated pneumonia to be 11,897 dollars (95

240 ilation, moving from the current standard of ventilator-associated pneumonia to broader complications

241 ntral line-associated bloodstream infection, ventilator-associated pneumonia, urinary tract infection

242 more stringent criteria for surveillance of ventilator-associated pneumonia, use of the administrati

243 p technique can be used for the diagnosis of ventilator-associated pneumonia using bronchoalveolar la

244 Ventilator-associated pneumonia (VAP) carries significan

245 Ventilator-associated pneumonia (VAP) causes substantial

246 patients started on antibiotics for possible ventilator-associated pneumonia (VAP) do not have pneumo

247 y of topical chlorhexidine for prevention of ventilator-associated pneumonia (VAP) in a meta-analysis

248 ual gastric volume is recommended to prevent ventilator-associated pneumonia (VAP) in patients receiv

249 lized forms of colistin for the treatment of ventilator-associated pneumonia (VAP) in patients withou

250 Ventilator-associated pneumonia (VAP) is a common and se

251 Ventilator-associated pneumonia (VAP) is a common health

252 Ventilator-associated pneumonia (VAP) is a common nosoco

253 Ventilator-associated pneumonia (VAP) is a leading cause

254 Rapid and accurate diagnosis of ventilator-associated pneumonia (VAP) is a major challen

255 Ventilator-associated pneumonia (VAP) is a target for he

256 Ventilator-associated pneumonia (VAP) is among the most

257 Accurate surveillance of ventilator-associated pneumonia (VAP) is hampered by sub

258 Diagnosis of ventilator-associated pneumonia (VAP) is imprecise.

259 The occurrence of ventilator-associated pneumonia (VAP) is linked to the a

260 Ventilator-associated pneumonia (VAP) is notoriously dif

261 Ventilator-associated pneumonia (VAP) is the most common

262 Ventilator-associated pneumonia (VAP) is the most common

263 The complexity and subjectivity of ventilator-associated pneumonia (VAP) surveillance limit

264 lly over a 3-week period from a patient with ventilator-associated pneumonia (VAP) who received clind

265 ssociated urinary tract infections (CAUTIs), ventilator-associated pneumonia (VAP), and Clostridium d

266 Ventilator-associated pneumonia (VAP), bloodstream infec

267 sk for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), including special

268 lator-associated tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP).

269 lator-associated tracheobronchitis (VAT) and ventilator-associated pneumonia (VAP).

270 nical respiratory support frequently develop ventilator-associated pneumonia (VAP).

271 ed patients decreases the risk of developing ventilator-associated pneumonia (VAP).

272 respiratory tract infections, most commonly ventilator-associated pneumonia (VAP; 88% [36/41]).

273 The rate of ventilator-associated pneumonia was 22.0 per 1,000 mecha

274 rol Consortium multidimensional approach for ventilator-associated pneumonia was associated with a si

275 Ventilator-associated pneumonia was confirmed bronchosco

276 Ventilator-associated pneumonia was confirmed by histolo

277 of aerosolized colistin in the treatment of ventilator-associated pneumonia was evaluated.

278 Mortality among patients with ventilator-associated pneumonia was higher among elderly

279 g phase 2, the multidimensional approach for ventilator-associated pneumonia was implemented at each

280 Each patient with suspected ventilator-associated pneumonia was included in the coho

281 Incidence of ventilator-associated pneumonia was lower in mechanicall

282 cases as ventilator-associated pneumonia/not ventilator-associated pneumonia was nearly random (Fleis

283 Ventilator-associated pneumonia was the most common type

284 Sensitivity and specificity of diagnosing ventilator-associated pneumonia were 0.92 and 0.28 for v

285 The corresponding rates of ventilator-associated pneumonia were 8.5 vs. 1.2 cases p

286 -producing Enterobacteriaceae involvement in ventilator-associated pneumonia were 85.0% and 95.7%, re

287 ogy of nosocomial bloodstream infections and ventilator-associated pneumonia were also compared betwe

288 Other risk factors for mortality in ventilator-associated pneumonia were diabetes mellitus,

289 The odds of developing P. aeruginosa ventilator-associated pneumonia were eight times higher

290 the prevention, diagnosis, and treatment of ventilator-associated pneumonia were implemented using a

291 Patients with ventilator-associated pneumonia were more likely to be b

292 When data from the seven trials reporting ventilator-associated pneumonia were pooled, ventilator-

293 s study was to compare the observed rates of ventilator-associated pneumonia when using the National

294 ise was less common in elderly patients with ventilator-associated pneumonia, whereas more episodes a

295 eter-associated urinary tract infection, and ventilator-associated pneumonia), which have traditional

296 ith a statistically significant reduction in ventilator-associated pneumonia, which had not been achi

297 Of 50 patients with P. aeruginosa ventilator-associated pneumonia who underwent surveillan

298 tween transfusion of fresh frozen plasma and ventilator-associated pneumonia with shock (relative ris

299 with shock (relative risk 5.42, 2.73-10.74), ventilator-associated pneumonia without shock (relative

300 nterventions beneficial to the prevention of ventilator-associated pneumonia would therefore have a s